Cardiovascular Effects on Incretin Based Anti-Diabetics

Nancy J. Brown, M.D.
Hugh Jackson Morgan Professor of Medicine and Pharmacology
Chair, Department of Medicine
Vanderbilt University Medical Center
Physician-in-Chief, Vanderbilt Hospital

Sponsorship: This activity is sponsored by Wake Forest School of Medicine.

Accreditation: The Wake Forest School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit: The Wake Forest School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives: At the conclusion of this CME activity, the learner should be better able to:
1. Have an understanding of cardiovascular physiology underlying the effects of incretin based therapies.
2. Illustrate methods of understanding pharmacological mechanisms in humans.

Full Disclosure: As an accredited CME provider, Wake Forest School of Medicine requires that everyone comply with the Accreditation Requirements of the Accreditation Council for Continuing Medical Education (ACCME), which includes the Standards for Commercial Support: Standards to Ensure Independence in CME Activities. All planning committee members (both faculty and staff) and speakers/presenters/teachers have been asked to disclose any significant financial interest or relationship they have with the manufacturer(s) of any commercial product or service. The Standards require all presentations be free of commercial bias and any information regarding commercial products or services be based on scientific methods generally accepted by the medical community. When discussing therapeutic options, speakers/presenters/teachers have been asked to use only generic names. If it is necessary to use a trade name, then those of several companies are to be used. Further, should presentations include discussion of any unlabeled/investigational use of a commercial product, speakers/presenters/teachers are required to disclose that information to the audience. In the spirit of full disclosure, the following information is provided to all attendees:

Planning Committee: Dr. Gary E. Rosenthal has nothing to disclose in regard to this activity. No other member of the Planning Committee has anything to disclose.

Speaker/Presenter/Teacher: Dr. Nancy J. Brown would like to disclose the following in regard to this activity.
Grant/Research Support: Novo Nordisk
Consultant: Novartis

CONTACS
Gary E. Rosenthal, MD, FACP
Coordinator - 336-716-2715

Deanna N. Jones, MD
ACM Coordinator – 336-713-9207

Ruth Caudle
Admin. Support - 336-716-5039